We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celgene Corporation reported better-than-expected results for the third quarter of 2018, propelled by a jump in psoriasis drug Otezla. Lead drug, Revlimid too maintained momentum for the company. Consequently, the company raised its annual guidance.
After a string of setbacks in early 2018, the company’s performance picked up, giving investors something to cheer about. The company's shares were up in pre-market trading.
Celgene’s stock has lost 28.4% in the year so far compared with the industry’s decline of 20.2%.
The company reported adjusted earnings of $2.29 per share, which beat the Zacks Consensus Estimate of $2.25, up from $1.91 in the year-ago quarter.
Total revenues grew 18.4% to $3.89 billion in the reported quarter and beat the Zacks Consensus Estimate of $3.83 billion.
Revlimid Drives Growth
Net product sales increased 18% year over year to $3.89 billion. Net sales of Revlimid were $2.4 billion, reflecting 18% year-over-year increase. The drug performed well both in the United States (up 22%) and international markets (up 9%). Growth in the reported quarter was driven by increases in market share and extended treatment duration.
Net sales of another cancer drug, Abraxane, increased 15% to $288 million, owing to increases in demand and customer buying patterns. Pomalyst/Imnovid came in at $513 million, up 23%. Sales were driven by increase in market share and duration.
Sales of psoriasis drug, Otezla surged 40% in the reported quarter to $432 million and surpassed the Zacks Consensus Estimate of $372 million. Sales in the United States were driven by increases in demand, with continued benefit from expanded market access and higher channel inventory levels. All other product sales (including Istodax, Thalomid, Vidaza and an authorized generic version of Vidaza in the United States) totaled $208 million in the quarter under review, down from $226 million in the year-ago quarter.
Adjusted research and development expenses increased 35.8% to $948 million, driven by the inclusion of R&D expenses associated with the acquisition of Juno and regulatory submission-related work on multiple programs. Adjusted selling, general and administrative expenses increased 23.2% to $642 million.
Pipeline Update
Celgene is evaluating bb2121 in collaboration with bluebird bio (BLUE - Free Report) for the treatment of multiple myeloma. The program is advancing well with the phase II MM-002 and phase III MM-003 trials.
Celgene and partner Acceleron Pharma earlier reported positive results from two phase III studies on luspatercept — BELIEVE and MEDALIST. Luspatercept achieved all primary and key secondary endpoints in the phase III MEDALIST and BELIEVE trials in patients with low-to-intermediate risk myelodysplastic syndromes (MDS) and transfusion-dependent beta-thalassemia, respectively. The company will present these data at the 2018 American Society of Hematology (ASH) annual meeting in December.
The phase III COMMANDS front-line trial, evaluating luspatercept in erythropoiesis-stimulating agent (ESA)-naïve, very low, low or intermediate risk MDS patients, was initiated in the third quarter.
2018 Outlook Updated
Celgene now anticipates earnings per share of $8.75-$8.80 in 2018, up from the previous estimate of $8.70-$8.75. The Zacks Consensus Estimate for earnings is $8.79. Net revenues are now estimated around $15.2 billion, up from the earlier projection of $15 billion, while the Zacks Consensus Estimate for the same is pegged at $15.1 billion.
Revlimid sales are projected at $9.7 billion and Abraxane sales at around $1 billion. Pomalyst’s revenues are expected to be $2.0 billion, whereas Otezla sales are projected at $1.6 billion, up from $1.5 billion projected earlier.
Our Take
Celgene’s third-quarter results were strong as the company comfortably beat on both sales and earnings. Otezla led the performance in the third quarter. Revlimid sales were impressive as well. The increase in annual guidance on the back of impressive Otezla sales should boost investors’ confidence.
Celgene’s efforts to develop its pipeline is encouraging as well. The company was on the look-out for new deals and acquisitions, given a lacklustre 2017, and the Juno acquisition was a step toward that direction. Earlier, Celgene announced a global collaboration with Prothena (PRTA - Free Report) to develop new therapies for a broad range of neurodegenerative diseases, primarily focused on three proteins implicated in the pathogenesis of several neurodegenerative diseases, including tau, TDP-43 and an undisclosed target.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Celgene (CELG) Tops Q3 Earnings & Sales Estimates, Ups View
Celgene Corporation reported better-than-expected results for the third quarter of 2018, propelled by a jump in psoriasis drug Otezla. Lead drug, Revlimid too maintained momentum for the company. Consequently, the company raised its annual guidance.
After a string of setbacks in early 2018, the company’s performance picked up, giving investors something to cheer about. The company's shares were up in pre-market trading.
Celgene’s stock has lost 28.4% in the year so far compared with the industry’s decline of 20.2%.
The company reported adjusted earnings of $2.29 per share, which beat the Zacks Consensus Estimate of $2.25, up from $1.91 in the year-ago quarter.
Total revenues grew 18.4% to $3.89 billion in the reported quarter and beat the Zacks Consensus Estimate of $3.83 billion.
Revlimid Drives Growth
Net product sales increased 18% year over year to $3.89 billion. Net sales of Revlimid were $2.4 billion, reflecting 18% year-over-year increase. The drug performed well both in the United States (up 22%) and international markets (up 9%). Growth in the reported quarter was driven by increases in market share and extended treatment duration.
Net sales of another cancer drug, Abraxane, increased 15% to $288 million, owing to increases in demand and customer buying patterns. Pomalyst/Imnovid came in at $513 million, up 23%. Sales were driven by increase in market share and duration.
Sales of psoriasis drug, Otezla surged 40% in the reported quarter to $432 million and surpassed the Zacks Consensus Estimate of $372 million. Sales in the United States were driven by increases in demand, with continued benefit from expanded market access and higher channel inventory levels.
All other product sales (including Istodax, Thalomid, Vidaza and an authorized generic version of Vidaza in the United States) totaled $208 million in the quarter under review, down from $226 million in the year-ago quarter.
Adjusted research and development expenses increased 35.8% to $948 million, driven by the inclusion of R&D expenses associated with the acquisition of Juno and regulatory submission-related work on multiple programs. Adjusted selling, general and administrative expenses increased 23.2% to $642 million.
Pipeline Update
Celgene is evaluating bb2121 in collaboration with bluebird bio (BLUE - Free Report) for the treatment of multiple myeloma. The program is advancing well with the phase II MM-002 and phase III MM-003 trials.
Celgene and partner Acceleron Pharma earlier reported positive results from two phase III studies on luspatercept — BELIEVE and MEDALIST. Luspatercept achieved all primary and key secondary endpoints in the phase III MEDALIST and BELIEVE trials in patients with low-to-intermediate risk myelodysplastic syndromes (MDS) and transfusion-dependent beta-thalassemia, respectively. The company will present these data at the 2018 American Society of Hematology (ASH) annual meeting in December.
The phase III COMMANDS front-line trial, evaluating luspatercept in erythropoiesis-stimulating agent (ESA)-naïve, very low, low or intermediate risk MDS patients, was initiated in the third quarter.
2018 Outlook Updated
Celgene now anticipates earnings per share of $8.75-$8.80 in 2018, up from the previous estimate of $8.70-$8.75. The Zacks Consensus Estimate for earnings is $8.79. Net revenues are now estimated around $15.2 billion, up from the earlier projection of $15 billion, while the Zacks Consensus Estimate for the same is pegged at $15.1 billion.
Revlimid sales are projected at $9.7 billion and Abraxane sales at around $1 billion. Pomalyst’s revenues are expected to be $2.0 billion, whereas Otezla sales are projected at $1.6 billion, up from $1.5 billion projected earlier.
Our Take
Celgene’s third-quarter results were strong as the company comfortably beat on both sales and earnings. Otezla led the performance in the third quarter. Revlimid sales were impressive as well. The increase in annual guidance on the back of impressive Otezla sales should boost investors’ confidence.
Celgene’s efforts to develop its pipeline is encouraging as well. The company was on the look-out for new deals and acquisitions, given a lacklustre 2017, and the Juno acquisition was a step toward that direction. Earlier, Celgene announced a global collaboration with Prothena (PRTA - Free Report) to develop new therapies for a broad range of neurodegenerative diseases, primarily focused on three proteins implicated in the pathogenesis of several neurodegenerative diseases, including tau, TDP-43 and an undisclosed target.
Zacks Rank
Celgene currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>